Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gelatin-iodine contrast medium is an investigational radiopaque formulation developed by Dazhou Central Hospital for use in interventional oncology. It is a combination of gelatin, a proteinaceous substance derived from collagen that provides viscosity and potential embolic properties, and an iodinated contrast medium that provides radiopacity. In clinical trials, it is used as a dopant for ethanol to create a "drug-doped ethanol chemical dissolution agent" for the percutaneous treatment of small hepatocellular carcinoma (HCC). This approach aims to improve the localization and monitoring of ethanol dissolution therapy by ensuring the therapeutic agent remains within the tumor boundaries and is visible under imaging guidance such as CT or fluoroscopy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gelatin-iodine contrast medium.